Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Roche Diagnostics introduces STAT immunoassays for cardiac biomarker testing

Roche Diagnostics announced today that it has introduced a complete battery of STAT immunoassays for cardiac biomarker testing on the cobas 6000 analyzer series, an integrated system designed for diagnostic labs with medium testing volumes.

From Roche Sequencing and Life Science 17 Sep 2010

HFSA to discuss 'Designing the Medical Home for Heart Failure Patients' at Scientific Meeting

The 14th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a discussion titled "Designing the Medical Home for Heart Failure Patients." Contributors Dr. Mary Norine Walsh and Dr. Larry A. Allen will describe treatment and care strategies in the medical home model and how they impact both patients and caregivers.

16 Sep 2010

Recommendations for developing novel therapies for hypertrophic cardiomyopathy

16 Sep 2010

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of SCOUT and the weight loss medication sibutramine (sold as Meridia® in the United States).

16 Sep 2010

New approach to evaluate risk of cardiovascular disease

A new approach to evaluating a person's risk of cardiovascular disease, stroke, high blood pressure, or heart failure is reported this month in the International Journal of Data Mining, Modelling and Management. The technique uses fuzzy logic to teach a neural network computer program to analyze patient data and spot correlations that can be translated into a risk factor for an individual.

16 Sep 2010

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.

16 Sep 2010

Study finds GRK2 molecule promotes cell death after heart attack

A molecule known to be involved in progressive heart failure has now been shown to also lead to permanent damage after a heart attack, according to researchers at Thomas Jefferson University.

16 Sep 2010

Researchers recommend mechanism to identify hypertrophic cardiomyopathy

An abrupt, fatal heart attack in a young athlete on the playing field is a tragedy destined to repeat itself over and over until more is understood about hypertrophic cardiomyopathy (HCM), a genetic disorder that is the most common cause of sudden death in young people but which affects people of all ages. So says a task force of cardiologists and cardiac biologists, headed by Thomas L. Force, M.D., James C. Wilson Professor of Medicine at Thomas Jefferson University, in the September 14th online edition of the journal Circulation.

15 Sep 2010

Heart patients with Type D personality at higher risk of future cardiovascular problems

Heart patients with the "distressed" (Type D) personality profile may face a higher risk of future cardiovascular problems, according to a summary article published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

15 Sep 2010

$Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy$

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

15 Sep 2010

FDA approves Krystexxa drug to treat gout

The U.S. Food and Drug Administration approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

15 Sep 2010

Long-term stenting of aortic coarctation yields 77% success rate

Researchers from the Congenital Cardiovascular Interventional Study Consortium (CCISC) who evaluated the intermediate and long-term results of stent implantation for aortic coarctation found that cumulative intermediate success was 86%, and cumulative long-term success was 77%. Results of this study appear in the October issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

14 Sep 2010

Public reporting of quality information helps consumers choose the right physician: Study

When looking for a new physician, patients are often encouraged to select those who are board certified or who have not made payments on malpractice claims. Yet these characteristics are not always a good predictor of which physicians will provide the highest quality medical care, according to a new study from the RAND Corporation, a nonprofit research organization, and the University of Pittsburgh School of Medicine.

14 Sep 2010

Study shows Americans with muscular dystrophy live longer than African-Americans

A new study shows that white men and boys are living longer with muscular dystrophy due to technological advances in recent years, but that the lives of African-American men and boys with muscular dystrophy have not been extended at the same rate. The research will be published in the September 14, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

14 Sep 2010

HFSA Meeting to discuss genomic diseases similarities in animals, humans

The 14th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a discussion on the similarities in genomic diseases between animals and humans, titled "Comparative Genomics and Human Disease,Some Recent Contributions from Zoos."

14 Sep 2010

New insight into most common form of congenital heart disease

Repairing small, seemingly benign holes in a child's heart may be more clinically important than previously thought, as dysfunction could be lurking out of sight. These are the findings from a study conducted by doctors and researchers at Nationwide Children's Hospital and the Ohio State University Medical Center examining a subset of the most common form of congenital heart disease, ventricular septal defect.

14 Sep 2010

HealthWyse, Cardiocom partner to integrate patient information into clinical software

HealthWyse, a leading provider of home health and hospice software and services, announced today that it has partnered with Cardiocom, a leader in home telehealth solutions, to seamlessly integrate patient information into HealthWyse's clinical software.

13 Sep 2010

Medtronic launches CareLink Network for Heart Failure

Medtronic, Inc. today introduced the CareLink® Network for Heart Failure, an extension of the world's largest remote implantable cardiac device monitoring system, that will be available this fall for heart failure clinicians.

13 Sep 2010

AultCare reports positive results from Cardiocom program

AultCare has been using patient telemonitoring for six years and has, in partnership with Cardiocom, released a white paper entitled, "AultCare Sees Positive Results from Cardiocom Program."

13 Sep 2010

First US implantation of Medtronic Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring

David H. Adams, MD, Marie-Jos-e and Henry R. Kravis Professor and Chairman of the Department of Cardiothoracic Surgery at The Mount Sinai Medical Center, has performed the first implantation of the Medtronic Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring in the United States. Dr. Adams invented the ring, which was recently approved by the Food and Drug Administration.

13 Sep 2010

Heart Failure News and Research

Further Reading

Roche Diagnostics introduces STAT immunoassays for cardiac biomarker testing

HFSA to discuss 'Designing the Medical Home for Heart Failure Patients' at Scientific Meeting

Recommendations for developing novel therapies for hypertrophic cardiomyopathy

Abbott issues statement in response to FDA's mixed vote for weight loss medication sibutramine

New approach to evaluate risk of cardiovascular disease

Relypsa announces positive results from Phase 2 clinical trial of RLY5016

Study finds GRK2 molecule promotes cell death after heart attack

Researchers recommend mechanism to identify hypertrophic cardiomyopathy

Heart patients with Type D personality at higher risk of future cardiovascular problems

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

FDA approves Krystexxa drug to treat gout

Long-term stenting of aortic coarctation yields 77% success rate

Public reporting of quality information helps consumers choose the right physician: Study

Study shows Americans with muscular dystrophy live longer than African-Americans

HFSA Meeting to discuss genomic diseases similarities in animals, humans

New insight into most common form of congenital heart disease

HealthWyse, Cardiocom partner to integrate patient information into clinical software

Medtronic launches CareLink Network for Heart Failure

AultCare reports positive results from Cardiocom program

First US implantation of Medtronic Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News